| Literature DB >> 31477741 |
Young-Rak Cho1, Soe Hee Ann2, Ki-Bum Won3, Gyung-Min Park2, Yong-Giun Kim2, Dong Hyun Yang4, Joon-Won Kang4, Tae-Hwan Lim4, Hong-Kyu Kim5, Jaewon Choe5, Seung-Whan Lee6, Young-Hak Kim6, Shin-Jae Kim2, Sang-Gon Lee2.
Abstract
This study evaluated the relationship of insulin resistance (IR) and glycemic control status to the presence and severity of coronary artery disease (CAD) according to diabetes. The relationship of IR parameters including homeostatic model assessment of IR (HOMA-IR), triglyceride-glucose (TyG) index, and triglyceride-to-high density lipoprotein cholesterol ratio (TG/HDL), and hemoglobin A1C (HbA1C) level to CAD and obstructive CAD was evaluated in 5,764 asymptomatic subjects who underwent coronary computed tomographic angiography. Non-diabetics (n = 4768) and diabetics (n = 996) were stratified into four groups based on the quartiles of HOMA-IR and the TyG index and were grouped based on the TG/HDL cut-offs of 3.5, respectively. CAD and obstructive CAD were defined as the presence of any plaques and plaques with ≥50% stenosis, respectively. The prevalence of CAD (59.0% vs. 39.0%) and obstructive CAD (15.0% vs. 6.6%) was higher in diabetic than in non-diabetic patients (p < 0.001, respectively). In non-diabetic patients, the adjusted odds ratio for both CAD and obstructive CAD significantly increased, but only with higher TyG index quartiles. Unlike non-diabetics, the adjusted odds ratio for obstructive CAD significantly increased in diabetic patients with a TG/HDL level ≥ 3.5. The HbA1C, rather than IR parameters, was independently associated with both CAD and obstructive CAD in diabetics. In conclusion, among IR parameters, TyG index was independently associated with the presence of CAD and obstructive CAD in non-diabetic patients. In contrast, the glycemic control status, rather than IR, was importantly related to both CAD and obstructive CAD in established diabetic patients.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31477741 PMCID: PMC6718672 DOI: 10.1038/s41598-019-42700-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics.
| Non-diabetics (n = 4768) | Diabetics (n = 996) | p | |
|---|---|---|---|
| Age, yrs | 53.2 ± 7.7 | 55.8 ± 7.6 | <0.001 |
| Male, n (%) | 3393 (71.2) | 821 (82.4) | <0.001 |
| Body mass index, kg/m2 | 24.5 ± 2.9 | 25.4 ± 3.0 | <0.001 |
| Waist circumference, cm | 85.4 ± 8.3 | 88.9 ± 8.0 | <0.001 |
| Systolic blood pressure, mmHg | 119.0 ± 12.8 | 122.8 ± 13.5 | <0.001 |
| Diastolic blood pressure, mmHg | 76.2 ± 10.4 | 77.9 ± 10.0 | <0.001 |
| Hypertension, n (%) | 1580 (33.1) | 523 (52.5) | <0.001 |
| Dyslipidemia, n (%) | 1373 (28.8) | 438 (44.0) | <0.001 |
| Current-smoking, n (%) | 1083 (22.7) | 297 (29.8) | <0.001 |
| Total cholesterol, mg/dL | 197.0 ± 33.2 | 187.0 ± 38.1 | <0.001 |
| TG, mg/dL | 129.6 ± 77.3 | 159.4 ± 108.2 | <0.001 |
| HDL cholesterol, mg/dL | 53.7 ± 13.5 | 50.2 ± 12.4 | <0.001 |
| LDL cholesterol, mg/dL | 122.9 ± 29.2 | 113.4 ± 33.1 | <0.001 |
| Creatinine, mg/dL | 0.90 ± 0.16 | 0.91 ± 0.16 | 0.223 |
| Fasting glucose, mmol/L | 5.5 ± 0.5 | 7.5 ± 1.9 | <0.001 |
| HOMA-IR | 1.96 ± 1.23 | 3.38 ± 4.26 | <0.001 |
| TyG index | 8.63 ± 0.53 | 9.09 ± 0.65 | <0.001 |
| TG/HDL | 2.73 ± 2.13 | 3.52 ± 2.81 | <0.001 |
| HbA1C, % | 5.5 ± 0.4 | 6.8 ± 1.2 | <0.001 |
Values are given as the mean ± standard deviation or number (%).
CAD coronary artery disease, HbA1C hemoglobin A1C, HDL high-density lipoprotein, HOMA-IR homeostatic model assessment of insulin resistance, LDL low-density lipoprotein; TG triglyceride; TyG triglyceride-glucose.
Figure 1Comparison of non-diabetic patients and diabetic patients in terms of coronary atherosclerosis.
CCTA findings according to IR parameters.
| HOMA-IR quartile | TyG index quartile | TG/HDL | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | II | III | IV | P | I | II | III | IV | p | <3.5 | ≥3.5 | p | |
|
| n = 1194 | n = 1191 | n = 1193 | n = 1190 | n = 1197 | n = 1188 | n = 1193 | n = 1190 | n = 3638 | n = 1130 | |||
| CAD, n (%) | 382 (32.0) | 453 (38.0) | 492 (41.2) | 532 (44.7) | <0.001 | 352 (29.4) | 441 (37.1) | 528 (44.3) | 538 (45.2) | <0.001 | 1339 (36.8) | 520 (47.0) | <0.001 |
| Obstructive CAD, n (%) | 54 (4.5) | 80 (6.7) | 77 (6.5) | 103 (8.7) | 0.001 | 41 (3.4) | 77 (6.5) | 102 (8.5) | 94 (7.9) | <0.001 | 221 ((6.1) | 93 (8.2) | 0.011 |
| Plaque characteristics, n (%) | |||||||||||||
| Calcified plaque | 266 (22.3) | 306 (25.7) | 343 (28.8) | 366 (30.8) | <0.001 | 251 (21.0) | 313 (26.3) | 366 (30.7) | 351 (29.5) | <0.001 | 949 (26.1) | 332 (29.4) | 0.029 |
| Non-calcified plaque | 147 (12.3) | 197 (16.5) | 207 (17.4) | 221 (18.6) | <0.001 | 128 (10.7) | 172 (14.5) | 220 (18.4) | 252 (21.2) | <0.001 | 525 (14.4) | 247 (21.9) | <0.001 |
| Mixed plaque | 66 (5.5) | 82 (6.9) | 102 (8.5) | 117 (9.8) | <0.001 | 53 (4.4) | 83 (7.0) | 105 (8.8) | 126 (10.6) | <0.001 | 242 (6.7) | 125 (11.1) | <0.001 |
|
| n = 249 | n = 251 | n = 247 | n = 249 | n = 250 | n = 248 | n = 250 | n = 248 | n = 632 | n = 364 | |||
| CAD, n (%) | 144 (57.8) | 133 (53.0) | 138 (55.9) | 173 (69.5) | <0.001 | 137 (54.8) | 144 (58.1) | 158 (63.2) | 149 (60.1) | 0.277 | 367 (58.1) | 221 (60.7) | 0.414 |
| Obstructive CAD, n (%) | 32 (12.9) | 23 (9.2) | 43 (17.4) | 51 (20.5) | 0.002 | 34 (13.6) | 28 (11.3) | 40 (16.0) | 47 (19.0) | 0.098 | 84 (13.3) | 65 (17.9) | 0.052 |
| Plaque characteristics, n (%) | |||||||||||||
| Calcified plaque | 107 (43.0) | 101 (40.2) | 96 (38.9) | 139 (55.8) | <0.001 | 104 (41.6) | 112 (45.2) | 125 (50.0) | 102 (41.1) | 0.165 | 285 (45.1) | 158 (43.4) | 0.606 |
| Non-calcified plaque | 61 (24.5) | 55 (21.9) | 60 (24.3) | 73 (29.3) | 0.278 | 59 (23.6) | 55 (22.2) | 61 (24.4) | 74 (29.8) | 0.216 | 146 (23.1) | 103 (28.3) | 0.068 |
| Mixed plaque | 40 (16.1) | 33 (13.1) | 44 (17.8) | 48 (19.3) | 0.287 | 36 (14.4) | 35 (14.1) | 50 (20.0) | 44 (17.7) | 0.230 | 98 (15.5) | 67 (18.4) | 0.236 |
Values are given as the mean ± standard deviation or number (%).
CAD coronary artery disease, CCTA coronary computed tomographic angiography, HDL high-density lipoprotein, HOMA-IR homeostatic model assessment of insulin resistance, TG triglyceride, TyG triglyceride-glucose.
Association among the HOMA-IR, TyG index, TG/HDL, and coronary atherosclerosis according to diabetic status.
| Non-diabetics | Diabetics | |||||||
|---|---|---|---|---|---|---|---|---|
| CAD | Obstructive CAD | CAD | Obstructive CAD | |||||
| OR (95% CI) | P | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| By HOMA-IR quartile | ||||||||
| I | 1 | 1 | 1 | 1 | ||||
| II | 1.081 (0.892–1.309) | 0.426 | 1.287 (0.886–1.869) | 0.185 | 0.815 (0.550–1.207) | 0.307 | 0.768 (0.423–1.396) | 0.387 |
| III | 1.168 (0.961–1.421) | 0.119 | 1.242 (0.846–1.822) | 0.269 | 0.892 (0.593–1.342) | 0.584 | 1.512 (0.877–2.607) | 0.137 |
| IV | 1.203 (0.976–1.483) | 0.083 | 1.564 (1.057–2.313) | 0.025 | 1.413 (0.889–2.243) | 0.143 | 1.617 (0.907–2.882) | 0.103 |
| By TyG index quartile | ||||||||
| I | 1 | 1 | 1 | 1 | ||||
| II | 1.112 (0.916–1.351) | 0.283 | 1.661 (1.111–2.483) | 0.013 | 1.300 (0.873–1.937) | 0.197 | 0.929 (0.531–1.626) | 0.797 |
| III | 1.243 (1.020–1.514) | 0.031 | 1.938 (1.304–2.881) | 0.001 | 1.391 (0.922–2.099) | 0.116 | 1.329 (0.776–2.277) | 0.300 |
| IV | 1.299 (1.058–1.594) | 0.012 | 1.861 (1.232–2.811) | 0.003 | 1.160 (0.747–1.802) | 0.509 | 1.458 (0.830–2.564) | 0.190 |
| By cut-off 3.5 of TG/HDL | ||||||||
| <3.5 | 1 | 1 | 1 | 1 | ||||
| ≥3.5 | 1.176 (1.007–1.373) | 0.041 | 1.222 (0.930–1.605) | 0.149 | 1.034 (0.764–1.401) | 0.827 | 1.504 (1.015–2.230) | 0.042 |
Adjusted for age, sex, waist circumference, hypertension, dyslipidemia, current smoking status, and HbA1c level.
CAD coronary artery disease, CI confidence interval, HbA1C, hemoglobin A1C; HDL high-density lipoprotein, HOMA-IR homeostatic model assessment of insulin resistance, OR odds ratio, TG triglyceride, TyG triglyceride-glucose.
Association between the HbA1C level and coronary atherosclerosis according to diabetic status.
| Non-diabetics | Diabetics | |||||||
|---|---|---|---|---|---|---|---|---|
| CAD | Obstructive CAD | CAD | Obstructive CAD | |||||
| OR (95% CI) | P | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| Model 1 | 1.682 (1.438–1.968) | <0.001 | 1.817 (1.334–2.474) | <0.001 | 1.227 (1.095–1.375) | <0.001 | 1.395 (1.234–1.577) | <0.001 |
| Model 2 | 1.081 (0.904–1.291) | 0.394 | 1.227 (0.882–1.708) | 0.224 | 1.271 (1.127–1.434) | <0.001 | 1.457 (1.276–1.663) | 0.001 |
| Model 3 | 1.040 (0.868–1.245) | 0.671 | 1.160 (0.831–1.620) | 0.383 | 1.226 (1.085–1.387) | 0.001 | 1.440 (1.259–1.648) | 0.001 |
| Model 4 | 1.050 (0.878–1.257) | 0.591 | 1.159 (0.831–1.615) | 0.385 | 1.275 (1.119–1.454) | 0.001 | 1.404 (1.218–1.619) | 0.001 |
| Model 5 | 1.071 (0.896–1.280) | 0.454 | 1.197 (0.860–1.667) | 0.287 | 1.274 (1.126–1.441) | <0.001 | 1.422 (1.243–1.625) | <0.001 |
CAD coronary artery disease, CI confidence interval, HbA1C hemoglobin A1C, HDL high-density lipoprotein, HOMA-IR homeostatic model assessment of insulin resistance, OR odds ratio, TG triglyceride, TyG triglyceride-glucose.
Model 1: Unadjusted.
Model 2: Adjusted for age, sex, waist circumference, hypertension, dyslipidemia, and current smoking.
Model 3: Adjusted for age, sex, waist circumference, hypertension, dyslipidemia, current smoking, and HOMA-IR.
Model 4: Adjusted for age, sex, waist circumference, hypertension, dyslipidemia, current smoking, and TyG index.
Model 5: Adjusted for age, sex, waist circumference, hypertension, dyslipidemia, current smoking, and TG/HDL.